<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213677</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2019-243</org_study_id>
    <nct_id>NCT04213677</nct_id>
  </id_info>
  <brief_title>Dapagliflozin Efficacy and Action in PCOS</brief_title>
  <acronym>DEAP</acronym>
  <official_title>Efficacy and Safety of Dapagliflozin in Polycystic Ovary Syndrome: a Multicentre, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of dapagliflozin on improving
      insulin resistance and hyperandrogenemia in obesity women with polycystic ovary syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in insulin resistance over 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in insulin resistance assessed by insulin sensitivity index(HOMA-IR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in serum androgen level over 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in androgen level assessed by free testosterone index(FAI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in AUC (area under a curve) of glucose and insulin during the oral glucose tolerant test (OGTT)</measure>
    <time_frame>Baseline to 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum free testosterone(FT)</measure>
    <time_frame>Baseline to 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum sex hormone binding globulin(SHBG)</measure>
    <time_frame>Baseline to 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net change in total testosterone (TT) level</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net change in dehydroepiandrosterone-sulfate(DHEAS) level</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net change in androstenedione(AD) level</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>sulfate(DHEAS), luteinzing hormone(LH), androstenedione(AD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net change in luteinzing hormone(LH) level</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net change in waist circumference</measure>
    <time_frame>Baseline to 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Change in liver fat</measure>
    <time_frame>Baseline to 12 week</time_frame>
    <description>Liver fat will be assessed by liver fibroscan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ovulation rate assessed by serum progesterone</measure>
    <time_frame>Baseline to 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net change in body weight</measure>
    <time_frame>Baseline to 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net change in BMI</measure>
    <time_frame>Baseline to 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net change in glucose</measure>
    <time_frame>Baseline to 12 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin (Participants will receive dapagliflozin 10mg po qd).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Participants will receive placebo po qd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Participants will receive dapagliflozin 10mg po qd. Additionally, participants will receive lifestyle modification and nutrition education.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. women aged 18 to 45 years;

          2. Subjects with PCOS diagnosed by according to the Rotterdam criteria;

          3. BMI ≥24 kg/m2 and/ or Homeostatic model assessment of insulin resistance (HOMA-IR)
             with a cutoff ≥2.5;

          4. No pregnancy plan within the next 6 months;

        Exclusion Criteria:

          1. Congenital adrenal hyperplasia such as 21-hydroxylase deficiency, hyperprolactinemia,
             Cushing syndrome, androgen-producing tumors of the adrenal gland or ovary;

          2. Other endocrine diseases include poorly controlled thyroid diseases (hyperthyroidism
             or hypothyroidism), acromegaly, type 2 diabetes;

          3. Patients with a history of acute / chronic infection, severe cardio-cerebrovascular
             diseases and acute / chronic pancreatitis;

          4. Taking any antidiabetic medication that would affect insulin resistance or
             hyperandrogenemia (i.e. TZD, GLP-1RA, DPP-4i, metformin) in the past one month;

          5. Taking letrozole, clomiphene, oral contraceptive, glucocorticoid, gonadotropin,
             gonadotropin releasing hormone agonist, anti-androgen drug (spironolactone,
             cycloproterenone acetate, Flutamide etc.) and/or other drugs for PCOS in the past
             three months;

          6. History of recurrent urinary tract infection;

          7. History of malignant tumor;

          8. Currently participating in weight loss programs or weight change in the past 3 months
             (&gt; 5% current body weight) or have a history of gastrointestinal surgery.

          9. Serious liver dysfunction or chronic kidney disease (AST or ALT &gt; 3 times the upper
             limit of normal, or eGFR&lt;30 ml/min/1.73 m2);

         10. Women who are pregnant or plan to become pregnant;

         11. Subject is, in the judgment of the Investigator, unlikely to comply with the protocol
             or has any severe concurrent medical or psychological condition that may affect the
             interpretation of efficacy or safety data;

         12. Participation in other clinical trial in the 4 weeks before randomization;

         13. Patients who are unwilling or unable to give informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huijie Zhang, M.D.&amp;Ph.D</last_name>
    <phone>+86-020-61641635</phone>
    <email>huijiezhang2005@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huijie Zhang, MD,PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>May 24, 2020</last_update_submitted>
  <last_update_submitted_qc>May 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Huijie Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>SGLT2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

